These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24332674)

  • 41. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of adaptive servo-ventilation in patients with severe systolic heart failure.
    Takama N; Kurabayashi M
    J Cardiol; 2014 Apr; 63(4):302-7. PubMed ID: 24373869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).
    Abdin A; Komajda M; Borer JS; Ford I; Tavazzi L; Batailler C; Swedberg K; Rosano GMC; Mahfoud F; Böhm M;
    ESC Heart Fail; 2023 Oct; 10(5):2895-2902. PubMed ID: 37427483
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
    Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
    Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
    Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study).
    Schou M; Gustafsson F; Videbaek L; Andersen H; Toft J; Nyvad O; Ryde H; Fog L; Jensen JC; Nielsen OW; Lind-Rasmussen S; Abdulla J; Hildebrandt PR;
    Eur J Heart Fail; 2013 Jul; 15(7):818-27. PubMed ID: 23507787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).
    Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
    Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
    Weeda ER; Nguyen E; White CM
    Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study.
    Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J;
    ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
    J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk following hospitalization in stable chronic systolic heart failure.
    Abrahamsson P; Swedberg K; Borer JS; Böhm M; Kober L; Komajda M; Lloyd SM; Metra M; Tavazzi L; Ford I
    Eur J Heart Fail; 2013 Aug; 15(8):885-91. PubMed ID: 23460732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction.
    Huang D; Chan PH; Lam CC; Shea PC; Yiu KH; Tse HF; Siu CW
    J Heart Valve Dis; 2015 Jul; 24(4):433-5. PubMed ID: 26897811
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.